Clovis Oncology Stock News

Clovis Oncology (NASDAQ: CLVS ) stock is crashing on Wednesday as investors react to news of the company running out of cash! According to a recent filing from Clovis Oncology, there's a strong chance

Clovis Oncology Inc. shares CLVS, -73.37% plunged 75% Wednesday, after the Colorado-based biotech said it will not have sufficient liquidity to maintain operations beyond January of 2023. The company

Clovis Oncology continues to report positive clinical data from Rubraca and FAP-2286. I believe these updates make Clovis a prime acquisition target. I review some of the company's recent updates.

Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In a still-fresh press release, Clovis Oncology (NASDAQ: CLVS ) just announced that its Phase 3 trial for Rubraca, a prostate cancer treatment, achieved its primary endpoint. Moreover, Clovis plans to

Source: rafapress / Shutterstock.com Clovis Oncology (NASDAQ: CLVS ) stock is getting a boost on Wednesday as investors react to news of it reaching a two-year clinical supply agreement. That agreemen

Gainers SOBR Safe, Inc. (NASDAQ: SOBR) shares surged 232.8% to settle at $3.03 on Tuesday following a report suggesting The National Transportation Safety Board is recommending that NHTSA require pas

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 51% to $0.4957. Crown ElectroKinetics, last month, posted a Q4 net loss of $4.5 million. Virax Biolabs Group Limited (NASDAQ: VRAX) g

Gainers BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) rose 58.2% to $8.70 in pre-market trading. BYND Cannasoft shares jumped over 32% on Monday after the company announced it has signed a share pur

Clovis (CLVS) files regulatory applications in the United States and Europe seeking label expansion for its sole marketed drug as a first-line maintenance treatment in advanced ovarian cancer.

Clovis (CLVS) files regulatory applications in the United States and Europe seeking label expansion for its sole marketed drug as a first-line maintenance treatment in advanced ovarian cancer.

Shares of Clovis Oncology (NASDAQ: CLVS ) stock are in focus after the company received positive results from its early Phase 3 clinical trial. However, shares of CLVS stock are down about 5% today af

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split. InMed Pharmaceuticals Inc. (NASDAQ: INM)

The biotech delivers some highly encouraging news on the clinical front.